Adam Mostafa

Advisory Council

Adam Mostafa

Finance & Business Development

Mr. Adam Mostafa is the Chief Financial Officer at Abpro Corporation.  Before Abpro, Mr. Mostafa served as Managing Director of Healthcare Investment Banking Group at Cantor Fitzgerald, L.P with responsibility for origination of life sciences transactions (FOs, Debt, IPOs, M&A) including: Infinity Pharmaceuticals (INFI), Fibrocell (FCSC), Cellular Biomedicine Group (CBMG), Neothetics (NEOT), Cyclacel (CYCC), Cytosorbents (CTSO), Auris Medical (EARS), Galmed Pharmaceuticals (GLMD), T2 Biosystems (TTOO), Bionomics (BNO), Juventas Therapeutics (private), Altimmune (private), Biocardia (private).  He served as the Senior Vice President of Healthcare Investment Banking at Needham & Company, LLC from June 2011 until January 2015, overseeing public financing and 3 private M&A transactions as lead banker (aesthetic device sell-side, cardiovascular therapeutic sell-side and point-of-care diagnostics sell-side). Mr. Mostafa’s prior experience includes Vice President of M.M. Dillon & Co., LLC (previously known as CRT Investment Banking), and associate posts at CRT Capital Group, AQR Capital Management, and Citigroup. Adam Mostafa completed his B.A. in Mathematical Economics in 2001 at Brown University